$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000158364819000075 Filed on November 12, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$17.27M	$15.13M	$8.345M
YoY Change	251.73%	81.33%	112.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.480M	$4.840M	$4.750M
YoY Change	-1.75%	1.89%	66.67%
% of Gross Profit
Research & Development	$14.12M	$13.21M	$11.40M
YoY Change	8.62%	15.88%	82.15%
% of Gross Profit
Depreciation & Amortization	$260.0K	$160.0K	$130.0K
YoY Change	62.5%	23.08%	116.67%
% of Gross Profit
Operating Expenses	$18.60M	$18.05M	$16.15M
YoY Change	5.92%	11.75%	77.25%
Operating Profit		-$2.914M	-$7.804M
YoY Change		-62.66%	50.54%
Interest Expense	$380.0K	$377.0K	$504.0K
YoY Change	-19.15%	-25.2%
% of Operating Profit
Other Income/Expense, Net	$180.0K	-$55.00K	$1.147M
YoY Change	-45.45%	-104.8%	-166.34%
Pretax Income	-$770.0K	-$2.592M	-$6.153M
YoY Change	-93.5%	-57.87%	-10.99%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$770.0K	-$2.592M	-$6.153M
YoY Change	-93.41%	-57.87%	-12.83%
Net Earnings / Revenue	-4.46%	-17.13%	-73.73%
Basic Earnings Per Share
Diluted Earnings Per Share	-$14.50K	-$52.48K	-$113.7K
COMMON SHARES
Basic Shares Outstanding	54.98M shares	49.39M shares	54.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$104.2M	$86.20M	$137.3M
YoY Change	-18.66%	-37.22%	52.73%
Cash & Equivalents	$62.26M	$46.07M	$89.48M
Short-Term Investments	$41.90M	$40.20M	$47.80M
Other Short-Term Assets	$4.100M	$4.800M	$4.200M
YoY Change	-10.87%	14.29%	50.0%
Inventory
Prepaid Expenses
Receivables	$6.787M	$6.952M	$5.338M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$115.0M	$97.97M	$146.8M
YoY Change	-15.05%	-33.28%	54.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.50M	$11.01M	$4.687M
YoY Change	286.25%	134.86%	35.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change
Other Assets	$3.146M	$7.770M	$121.0K
YoY Change	245.71%	6321.49%	-6.4%
Total Long-Term Assets	$26.08M	$18.78M	$4.808M
YoY Change	337.72%	290.56%	34.12%
TOTAL ASSETS
Total Short-Term Assets	$115.0M	$97.97M	$146.8M
Total Long-Term Assets	$26.08M	$18.78M	$4.808M
Total Assets	$141.1M	$116.8M	$151.7M
YoY Change	-0.17%	-23.02%	53.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.803M	$5.436M	$2.693M
YoY Change	73.22%	101.86%	3.51%
Accrued Expenses	$9.944M	$7.170M	$5.981M
YoY Change	9.11%	19.88%	17.28%
Deferred Revenue	$11.26M	$27.24M
YoY Change	-68.39%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.00M	$39.85M	$40.59M
YoY Change	-43.83%	-1.84%	3.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$12.08M	$32.00K
YoY Change	-100.0%	37656.25%	-26.37%
Total Long-Term Liabilities	$0.00	$12.08M	$32.00K
YoY Change	-100.0%	37656.25%	-26.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.00M	$39.85M	$40.59M
Total Long-Term Liabilities	$0.00	$12.08M	$32.00K
Total Liabilities	$89.75M	$96.11M	$101.4M
YoY Change	-11.5%	-5.21%	7.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$174.2M	-$173.4M	-$135.4M
YoY Change	18.43%	28.08%	5.93%
Common Stock	$227.5M	$194.7M	$188.7M
YoY Change	19.76%	3.2%	39.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$51.35M	$20.64M	$50.26M
YoY Change
Total Liabilities & Shareholders Equity	$141.1M	$116.8M	$151.7M
YoY Change	-0.17%	-23.02%	53.4%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$770.0K	-$2.592M	-$6.153M
YoY Change	-93.41%	-57.87%	-12.83%
Depreciation, Depletion And Amortization	$260.0K	$160.0K	$130.0K
YoY Change	62.5%	23.08%	116.67%
Cash From Operating Activities	-$13.98M	-$12.65M	-$14.36M
YoY Change	54.3%	-11.91%	-140.8%
INVESTING ACTIVITIES
Capital Expenditures	-$1.170M	-$240.0K	-$320.0K
YoY Change	105.26%	-25.0%	10.34%
Acquisitions
YoY Change
Other Investing Activities	-$710.0K	$4.360M	$53.72M
YoY Change	-84.73%	-91.88%
Cash From Investing Activities	-$1.880M	$4.120M	$53.40M
YoY Change	-63.98%	-92.28%	-18513.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$50.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	31.67M	220.0K	270.0K
YoY Change	316600.0%	-18.52%	-86.7%
NET CHANGE
Cash From Operating Activities	-13.98M	-12.65M	-14.36M
Cash From Investing Activities	-1.880M	4.120M	53.40M
Cash From Financing Activities	31.67M	220.0K	270.0K
Net Change In Cash	15.81M	-8.310M	39.31M
YoY Change	-210.79%	-121.14%	6.42%
FREE CASH FLOW
Cash From Operating Activities	-$13.98M	-$12.65M	-$14.36M
Capital Expenditures	-$1.170M	-$240.0K	-$320.0K
Free Cash Flow	-$12.81M	-$12.41M	-$14.04M
YoY Change	50.88%	-11.61%	-139.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54975666	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	pirs	Accrued License Obligations AccruedLicenseObligations	2523000	USD
CY2019Q3	pirs	Accrued License Obligations AccruedLicenseObligations	60000	USD
CY2018Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	943000	USD
CY2019Q3	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1405000	USD
CY2018Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	378000	USD
CY2019Q3	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	424000	USD
	pirs	Additionsto Contractwith Customer Liability AdditionstoContractwithCustomerLiability	0	USD
CY2018Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	71941000	USD
CY2019Q3	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	54700000	USD
CY2019Q3	pirs	Lessee Operating Lease Initial Rentable Area LesseeOperatingLeaseInitialRentableArea	105000	sqft
CY2018Q4	pirs	Lessee Operating Lease Initial Rentable Area LesseeOperatingLeaseInitialRentableArea	105000	sqft
CY2018Q4	pirs	Lessee Operating Lease Rentable Area First Rightof Refusal LesseeOperatingLeaseRentableAreaFirstRightofRefusal	13400	sqft
CY2018Q4	pirs	Lessee Operating Lease Rentable Area Phase Four LesseeOperatingLeaseRentableAreaPhaseFour	22300	sqft
CY2018Q4	pirs	Lessee Operating Lease Rentable Area Phase Three LesseeOperatingLeaseRentableAreaPhaseThree	8600	sqft
CY2018Q4	pirs	Lessee Operating Lease Rentable Area Phase Two LesseeOperatingLeaseRentableAreaPhaseTwo	96400	sqft
CY2019Q4	pirs	Lessee Operating Lease Tenant Improvements Allowance LesseeOperatingLeaseTenantImprovementsAllowance	11200000	USD
CY2018Q4	pirs	Lessee Operating Lease Tenant Improvements Allowance LesseeOperatingLeaseTenantImprovementsAllowance	11200000	USD
CY2018Q4	pirs	Numberofleaserenewalterms Numberofleaserenewalterms	2	lease_renewal_option
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	222000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	198000	USD
CY2018Q3	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	472000	USD
	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	1555000	USD
CY2019Q3	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	634000	USD
	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	2043000	USD
	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9114000	USD
CY2019Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7170000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3350000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5436000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2701000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6952000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9114000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7170000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1945000	USD
CY2019Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1815000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3366000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3389000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2982000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-697000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	189929000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	194695000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1302000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3666000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1518000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4260000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3374000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3374000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21700000	shares
CY2018Q4	us-gaap	Assets Assets	141341000	USD
CY2019Q3	us-gaap	Assets Assets	116751000	USD
CY2019Q1	us-gaap	Assets Assets	143177000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	135382000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	97973000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	328000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	39847000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	40175000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74867000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46068000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	86200000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37878000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89482000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74867000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46068000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	51604000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-28799000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54151219	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49392706	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54151219	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49392706	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6632000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13430000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-582000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22413000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	35612000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	27242000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	53303000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	44179000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	56780000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	11000000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	17400000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-1641000	USD
CY2018Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	800000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-700000	USD
CY2019Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	200000	USD
CY2019Q3	us-gaap	Deferred Rent Asset Net Current DeferredRentAssetNetCurrent	12100000	USD
	us-gaap	Depreciation Depreciation	367000	USD
	us-gaap	Depreciation Depreciation	405000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1234000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2526000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2380000	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2430000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4748000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13878000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4835000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13956000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6153000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15220000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2592000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24698000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-148000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	902000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-19370000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	19365000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-853000	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	504000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1491000	USD
CY2019Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	377000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1332000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	800000	USD
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P0Y60M
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12Y6M
CY2018Q4	us-gaap	Liabilities Liabilities	101406000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	96109000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	104883000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141341000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116751000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143177000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48076000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	39848000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48504000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	501000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3658000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11719000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7992000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15072000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-2592000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38493000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-6153000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24698000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	16149000	USD
	us-gaap	Operating Expenses OperatingExpenses	42370000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	18046000	USD
	us-gaap	Operating Expenses OperatingExpenses	54836000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7804000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18183000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2914000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25827000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	945000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1036000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	910000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7770000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2030000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-506000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1096000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	374000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	377000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	100000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	100000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	27000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	546000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1636000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1908000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-506000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1096000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	374000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	377000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	27000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	546000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1636000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1908000	USD
CY2018Q3	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	91000	USD
CY2019Q3	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	0	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12082000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	376000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-90000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1147000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1472000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-55000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-203000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	67015000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	48762000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1133000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	178000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	314000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	105000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1286000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7907	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4574000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4778000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5290000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47207000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	64490000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	61767000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	983000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	218000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8415000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14397000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5049000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11008000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11401000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28492000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13211000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40880000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147066000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173405000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148707000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7873000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22541000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14498000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26966000	USD
CY2018Q3	us-gaap	Revenues Revenues	8345000	USD
	us-gaap	Revenues Revenues	24187000	USD
CY2019Q3	us-gaap	Revenues Revenues	15132000	USD
	us-gaap	Revenues Revenues	29009000	USD
CY2018Q4	us-gaap	Security Deposit SecurityDeposit	800000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3665000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4260000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	53240000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	40175000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	132000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	313000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	100000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	105000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	178000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	47207000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	144000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	983000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	121000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	218000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11522000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	55315000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	50261000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	39935000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	19485000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	20642000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	38294000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1096000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	469000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54089000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52721000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49353000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49805000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments and accounts receivable. The Company’s cash, cash equivalents and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001583648-19-000075-index-headers.html	Edgar Link	pending
0001583648-19-000075-index.html	Edgar Link	pending
0001583648-19-000075.txt	Edgar Link	pending
0001583648-19-000075-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pirs-20190930.xml	Edgar Link	completed
pirs-20190930.xsd	Edgar Link	pending
pirs-20190930_cal.xml	Edgar Link	unprocessable
pirs-20190930_def.xml	Edgar Link	unprocessable
pirs-20190930_lab.xml	Edgar Link	unprocessable
pirs-20190930_pre.xml	Edgar Link	unprocessable
pirs9-30x19ex311.htm	Edgar Link	pending
pirs9-30x19ex312.htm	Edgar Link	pending
pirs9-30x19ex321.htm	Edgar Link	pending
pirs9-30x19ex322.htm	Edgar Link	pending
pirs9-30x201910xq.htm	Edgar Link	pending
pirs_exhibit-102v3.htm	Edgar Link	pending
pirs_exhibit-102v3001.jpg	Edgar Link	pending
pirs_exhibit-102v3002.jpg	Edgar Link	pending
pirs_exhibit-102v3003.jpg	Edgar Link	pending
pirs_exhibit-102v3004.jpg	Edgar Link	pending
pirs_exhibit-102v3005.jpg	Edgar Link	pending
pirs_exhibit-102v3006.jpg	Edgar Link	pending
pirs_exhibit-102v3007.jpg	Edgar Link	pending
pirs_exhibit-102v3008.jpg	Edgar Link	pending
pirs_exhibit-102v3009.jpg	Edgar Link	pending
pirs_exhibit-102v3010.jpg	Edgar Link	pending
pirs_exhibit-102v3011.jpg	Edgar Link	pending
pirs_exhibit-102v3012.jpg	Edgar Link	pending
pirs_exhibit-102v3013.jpg	Edgar Link	pending
pirs_exhibit-102v3014.jpg	Edgar Link	pending
pirs_exhibit-102v3015.jpg	Edgar Link	pending
pirs_exhibit-102v3016.jpg	Edgar Link	pending
pirs_exhibit-102v3017.jpg	Edgar Link	pending
pirs_exhibit-102v3018.jpg	Edgar Link	pending
pirs_exhibit-102v3019.jpg	Edgar Link	pending
pirs_exhibit-102v3020.jpg	Edgar Link	pending
pirs_exhibit-102v3021.jpg	Edgar Link	pending
pirs_exhibit-103v1.htm	Edgar Link	pending
pirs_exhibit-103v1001.jpg	Edgar Link	pending
pirs_exhibit-103v1002.jpg	Edgar Link	pending
pirs_exhibit-103v1003.jpg	Edgar Link	pending
pirs_exhibit-103v1004.jpg	Edgar Link	pending
pirs_exhibit-103v1005.jpg	Edgar Link	pending
pirs_exhibit-103v1006.jpg	Edgar Link	pending
pirs_exhibit-103v1007.jpg	Edgar Link	pending
pirs_exhibit-103v1008.jpg	Edgar Link	pending
pirs_exhibit-103v1009.jpg	Edgar Link	pending
pirs_exhibit-103v1010.jpg	Edgar Link	pending
pirs_exhibit-103v1011.jpg	Edgar Link	pending
pirs_exhibit-103v1012.jpg	Edgar Link	pending
pirs_exhibit-103v1013.jpg	Edgar Link	pending
pirs_exhibit-103v1014.jpg	Edgar Link	pending
pirs_exhibit-103v1015.jpg	Edgar Link	pending
pirs_exhibit-31.htm	Edgar Link	pending
pirs_exhibit-31001.jpg	Edgar Link	pending
pirs_exhibit-31002.jpg	Edgar Link	pending
pirs_exhibit-31003.jpg	Edgar Link	pending
pirs_exhibit-31004.jpg	Edgar Link	pending
pirs_exhibit-31005.jpg	Edgar Link	pending
pirs_exhibit-31006.jpg	Edgar Link	pending
pirs_exhibit-31007.jpg	Edgar Link	pending
pirs_exhibit-31008.jpg	Edgar Link	pending
pirs_exhibit-31009.jpg	Edgar Link	pending
pirs_exhibit-31010.jpg	Edgar Link	pending
pirs_exhibit-31011.jpg	Edgar Link	pending
pirs_exhibit-31012.jpg	Edgar Link	pending
pirs_exhibit-32.htm	Edgar Link	pending
pirs_exhibit-32001.jpg	Edgar Link	pending
pirs_exhibit-32002.jpg	Edgar Link	pending
pirs_exhibit-32003.jpg	Edgar Link	pending
pirs_exhibit-32004.jpg	Edgar Link	pending
pirs_exhibit-32005.jpg	Edgar Link	pending
pirs_exhibit-32006.jpg	Edgar Link	pending
pirs_exhibit-32007.jpg	Edgar Link	pending
pirs_exhibit-32008.jpg	Edgar Link	pending
pirs_exhibit-32009.jpg	Edgar Link	pending
pirs_exhibit-32010.jpg	Edgar Link	pending
pirs_exhibit-32011.jpg	Edgar Link	pending
pirs_exhibit-32012.jpg	Edgar Link	pending
pirs_exhibit-32013.jpg	Edgar Link	pending
pirs_exhibit-32014.jpg	Edgar Link	pending
pirs_exhibit-32015.jpg	Edgar Link	pending
pirs_exhibit-32016.jpg	Edgar Link	pending
pirs_exhibit-32017.jpg	Edgar Link	pending
pirs_exhibit-32018.jpg	Edgar Link	pending
pirs_exhibit-32019.jpg	Edgar Link	pending
pirs_exhibit-32020.jpg	Edgar Link	pending
pirs_exhibit-32021.jpg	Edgar Link	pending
pirs_exhibit-32022.jpg	Edgar Link	pending
pirs_exhibit-32023.jpg	Edgar Link	pending
pirs_exhibit-32024.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2019 Q4 Form 10-Q Financial Statement

#000158364819000075 Filed on November 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2019 Q4 Form 10-Q Financial Statement

#000158364819000075 Filed on November 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs